舌下右美托咪定与安慰剂对双相障碍相关急性激越的疗效:一项随机临床试验
这项3期随机双盲安慰剂对照试验在美国15个中心纳入380例双相I型或II型障碍伴轻中度急性激越的成人患者,随机接受舌下右美托咪定180μg、120μg或安慰剂。用药2小时后,180μg组和120μg组PEC总分较基线的降幅均显著大于安慰剂组(两组P均<.001),治疗效应在用药20分钟后即出现。
要点
- 舌下右美托咪定180μg和120μg在2小时时PEC总分降幅均显著大于安慰剂(P<.001)。
- 180μg组与安慰剂组的最小二乘均值差为-5.4(97.5%CI,-6.6至-4.2)。
- 治疗效应在用药20分钟后出现,180μg组最小二乘均值差-1.1(P=.007)。
核心结论
- 在双相障碍相关轻中度激越患者中,与安慰剂相比,舌下膜剂型右美托咪定120μg或180μg在2小时时使激越评分出现显著更大的下降。
- 需要进一步研究以了解该治疗有效且可行的患者谱,并更好地理解所观察效应量的临床重要性。
研究设计与样本
- 3期、随机、双盲、安慰剂对照试验,在美国15个中心开展,入组时间为2020年2月24日至2020年4月27日,末次随访为2020年5月21日。
- 共380例双相I型或II型障碍成人患者被随机分组,362例完成研究。
- 参与者随机分为3组:舌下右美托咪定180μg组(n=127)、舌下右美托咪定120μg组(n=127)、安慰剂组(n=126)。
主要发现
- 380例随机患者的平均年龄45.6岁,女性占54.8%,Black个体占56.1%;378例(99.5%)自行使用研究药物并完成研究。
- 基线激越为轻至中度,总体平均PEC总分为18.0。
- 用药2小时后,PEC总分较基线的平均变化:舌下右美托咪定180μg组为-10.4,舌下右美托咪定120μg组为-9.0,安慰剂组为-4.9。
- 2小时时舌下右美托咪定组与安慰剂组的最小二乘均值差:180μg组为-5.4(97.5%CI,-6.6至-4.2),120μg组为-4.1(97.5%CI,-5.3至-2.9)(两剂量组与安慰剂比较P均<.001)。
- 舌下右美托咪定组患者在用药20分钟后即出现治疗效应(180μg组最小二乘均值差-1.1[97.5%CI,-2.0至-0.2],P=.007;120μg组-1.0[97.5%CI,-1.9至-0.1],P=.009)。
关键数值与推荐
- 主要疗效终点为用药2小时时阳性与阴性症状量表-兴奋成分(PEC)总分较基线的平均变化,总分范围5分(无激越)至35分(极重度)。
- 次要终点为药物组与安慰剂组相比PEC总分较基线出现统计学显著变化的最早时间。
- 针对主要疗效终点,为校正两个舌下右美托咪定剂量与安慰剂比较的多重性,每个剂量与安慰剂比较的双侧显著性水平设为.025。
- 不良事件发生率:右美托咪定180μg组为35.7%,120μg组为34.9%,安慰剂组为17.5%。
- 各组(180μg、120μg、安慰剂)最常见不良事件(≥5%):嗜睡(21.4%和20.6% vs 4.8%);口干(4.8%和7.1% vs 0.8%);低血压(6.3%和4.8% vs 0%);头晕(5.6%和5.6% vs 0.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以了解该治疗有效且可行的患者谱。
- 需要进一步研究以更好地理解所观察效应量的临床重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acute agitation is common in patients with bipolar disorder and requires urgent management to relieve distress and to prevent escalation to aggressive behavior. OBJECTIVE: To evaluate the effect of orally absorbed, sublingual dexmedetomidine, a selective α2A-adrenergic receptor agonist on symptoms of acute agitation in patients with bipolar disorder. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled trial conducted in 15 sites in the US with enrollment between February 24, 2020, and April 27, 2020, and final follow-up on May 21, 2020. A total of 380 adults with bipolar I or II disorder were randomized and 362 completed the study. INTERVENTIONS: Participants were randomized to 3 groups: sublingual dexmedetomidine 180 μg (n = 127), sublingual dexmedetomidine 120 μg (n = 127), or placebo (n = 126). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the mean change from baseline at 2 hours for the Positive and Negative Syndrome Scale-Excited Component (PEC) total score. The range of possible total scores is 5 (absence of agitation) to 35 (extremely severe). The secondary end point was the earliest time of a statistically significant change in PEC total score from baseline for the drug vs placebo. On the primary efficacy end point, to account for multiplicity associated with comparing 2 sublingual dexmedetomidine doses with placebo, the 2-sided significance level for each dose vs placebo was set at .025. RESULTS: Of 380 patients randomized (mean age, 45.6 years; 54.8% women; and 56.1% Black individuals), 378 (99.5%) self-administered the study medication and completed the study. Baseline agitation was mild to moderate, with an overall mean PEC total score of 18.0. Two hours after taking the medication, the mean changes from baseline in PEC total score were -10.4 for sublingual dexmedetomidine 180 μg, -9.0 for sublingual dexmedetomidine 120 μg, and -4.9 for placebo. Least-square mean differences from placebo in the sublingual dexmedetomidine groups at 2 hours were -5.4 (97.5% CI, -6.6 to -4.2) for 180 μg and -4.1 (97.5% CI, -5.3 to -2.9) for 120 μg (both doses P < .001 vs placebo). Treatment effects began 20 minutes after taking the medication among patients in the sublingual dexmedetomidine groups (least-square mean difference for 180 μg, -1.1 [97.5% CI, -2.0 to -0.2]; P = .007; for 120 μg, -1.0 [97.5% CI, -1.9 to -0.1]; P = .009). Adverse events occurred in 35.7% of patients taking 180 μg of dexmedetomidine, 34.9% taking 120 μg, and 17.5% taking placebo. The most common adverse events (≥5%) in the respective 180 μg, 120 μg, and placebo groups were somnolence (21.4% and 20.6% vs 4.8%); dry mouth (4.8% and 7.1% vs 0.8%); hypotension (6.3% and 4.8% vs 0%); and dizziness (5.6% and 5.6% vs 0.8%). CONCLUSIONS AND RELEVANCE: Among patients with mild to moderate agitation associated with bipolar disorder, treatment with a sublingual film formulation of dexmedetomidine 120 μg or 180 μg, compared with placebo, resulted in significantly greater reduction in the agitation score at 2 hours. Further research is needed to understand the spectrum of patients for whom this treatment would be effective and feasible and to better understand the clinical importance of the observed effect size. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04276883.
引用
- Preskorn SH, Zeller S, Citrome L, et al. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA. 2022. PMID: 35191924. doi:10.1001/jama.2022.0799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。